EQS-Adhoc: Vitruvia Medical AG: Half yearly results as per June 30th, 2024
|
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Results Vitruvia Medical AG half-year results as of June 30, 2024
Vitruvia Medical AG achieves results as expected in the first half of 2024. The Board of Directors confirms the forecast for the year as a whole. Vitruvia Medical AG is on target for the first six months of 2024. The result amounted to CHF -52,968.06 compared to CHF -150,464.24 in the previous year. Based on the expected results for the first half of 2024, the company's management confirms the outlook for the current full year. For this period, the Board of Directors expects consolidated sales of around EUR 2.0 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year.
End of Inside Information
25-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vitruvia Medical AG |
| Kesselackerstr. 18 | |
| 5611 Anglikon | |
| Switzerland | |
| Phone: | +41 44 915 33 78 |
| E-mail: | kontakt@vitruvia-med.com |
| Internet: | www.vitruvia-med.com |
| ISIN: | CH0461931419 |
| WKN: | A2PDWF |
| Listed: | Regulated Unofficial Market in Munich |
| EQS News ID: | 1954611 |
| End of Announcement | EQS News Service |
|
|
1954611 25-Jul-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 0,00 | 0,00 | 5,60 | 1,97 | 1,42 | 1,75 | 0,00 | |
| EBITDA1,2 | 0,00 | 0,00 | -0,96 | -0,75 | -0,91 | 0,06 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | -17,14 | -38,07 | -64,09 | 3,43 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | -1,31 | -7,69 | -1,24 | -0,37 | 0,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | -23,39 | -390,36 | -87,32 | -21,14 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | -1,54 | -7,71 | -1,48 | -0,54 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | -27,50 | -391,37 | -104,23 | -30,86 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | -0,21 | -0,78 | -0,67 | -0,10 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | -0,85 | -4,19 | -0,59 | -0,21 | -0,09 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: BDO
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Vitruvia Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2PDWF | CH0461931419 | AG | 2,51 Mio € | 11.05.2021 | 8FVC9778+HW | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -25,00 | 0,00 | 0,00 | -0,40 | -5,02 | -24,15 | 1,44 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 24.06.2024 | 30.09.2024 | 01.05.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +84,50% | +94,93% | -16,67% | -16,67% | -95,58% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
